Echo IQ is trading 5.81% down at A$0.73, with no company announcement dated September 21, 2026, or explicit explanation for the decline identified.

  • The latest material update, released September 17, outlined an administrative appeal, FDA Ombudsman review, and potential new 510(k) submission.
  • The update followed statistical-analysis concerns that delayed EchoSolv HF clearance.
  • It said technology and core functionality were unaffected and did not link the announcement to the September 21 decline.